Key Takeaways
- • Karimah Es Sabar, founding CEO and General Partner of Quark Venture LP, has joined Linearis Ventures as a Strategic Life Sciences and Venture Capital Advisor, expanding her role across the Canadian venture capital ecosystem.
- • Es Sabar brings 30 years of global business experience spanning biopharmaceutical industry, biotechnology startups, not-for-profit organizations, and venture capital, positioning her as a recognized leader in Canadian life sciences.
- • Quark Venture, the firm where Es Sabar serves as founding CEO, provides equity financing for innovative biotechnology companies, indicating Linearis Ventures' strategic focus on deepening life sciences investment capabilities.
- • Es Sabar's appointment reflects institutional demand for seasoned venture capital expertise in the life sciences sector, a critical area for both Canadian innovation competitiveness and institutional capital allocation.
- • Her advisory role at Linearis Ventures complements her existing leadership at Quark Venture LP and her involvement with the Global Health Sciences (GHS) Fund, suggesting a multi-platform approach to advancing life sciences venture capital.
Summary
Karimah Es Sabar, a highly recognized Canadian life sciences leader, has been appointed as a Strategic Life Sciences and Venture Capital Advisor to Linearis Ventures. The appointment leverages Es Sabar's extensive professional background spanning three decades across the global biopharmaceutical industry, biotechnology startups, not-for-profit organizations, and venture capital sectors.
Es Sabar's primary role remains as founding CEO and General Partner at Quark Venture LP, a Vancouver-based venture capital investment firm specializing in equity financing for innovative biotechnology companies. Her appointment to Linearis Ventures as a strategic advisor represents an expansion of her influence within the Canadian venture ecosystem and signals institutional commitment to strengthening life sciences investment capabilities.
Beyond her leadership at Quark Venture, Es Sabar holds additional responsibilities as Director of the Global Health Sciences (GHS) Fund and serves as a member of the board of the Information Technology and Innovation Foundation's Centre for Canadian Innovation and Competitiveness. These roles underscore her recognition as a thought leader in advancing Canadian life sciences competitiveness and innovation infrastructure.
The advisory appointment reflects broader institutional trends in venture capital, where established operators with deep sector expertise and networks are increasingly sought for strategic guidance roles. For institutional investors and family offices evaluating life sciences exposure through Canadian venture platforms, Es Sabar's appointment to Linearis Ventures may signal enhanced due diligence capabilities and sector navigation within the firm's advisory structure.
Es Sabar's primary role remains as founding CEO and General Partner at Quark Venture LP, a Vancouver-based venture capital investment firm specializing in equity financing for innovative biotechnology companies. Her appointment to Linearis Ventures as a strategic advisor represents an expansion of her influence within the Canadian venture ecosystem and signals institutional commitment to strengthening life sciences investment capabilities.
Beyond her leadership at Quark Venture, Es Sabar holds additional responsibilities as Director of the Global Health Sciences (GHS) Fund and serves as a member of the board of the Information Technology and Innovation Foundation's Centre for Canadian Innovation and Competitiveness. These roles underscore her recognition as a thought leader in advancing Canadian life sciences competitiveness and innovation infrastructure.
The advisory appointment reflects broader institutional trends in venture capital, where established operators with deep sector expertise and networks are increasingly sought for strategic guidance roles. For institutional investors and family offices evaluating life sciences exposure through Canadian venture platforms, Es Sabar's appointment to Linearis Ventures may signal enhanced due diligence capabilities and sector navigation within the firm's advisory structure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.